TRex Bio, Inc. (TRXB)
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Medical - Pharmaceuticals
TRex Bio Inc.
NASDAQ:TRXBHealthcare · Medical - Pharmaceuticals
-10.90%$13.81
AH Close$13.81+0.00%vs close
AH Close$13.81+0.00%vs close
Mkt Cap$379.02M
Float10.24M
O/S27.45M
Inst Own-
Dilution
MCap$379.02M
Float10.24M
O/S27.45M
Dilution